Viartril-S

Viartril-S

glucosamine

Manufacturer:

Mylan Healthcare

Distributor:

Antah Pharma
Full Prescribing Info
Contents
Crystalline glucosamine sulphate.
Description
Each 500-mg capsule contains crystalline glucosamine sulfate 628 mg equivalent to glucosamine sulfate 500 mg. Each sachet (powder for oral solution to be dissolved in water) contains crystalline glucosamine sulfate 1884 mg equivalent to glucosamine sulfate 1500 mg.
Indications/Uses
Treatment of osteoarthritis eg, pain and function limitation.
Dosage/Direction for Use
Capsule: One 500-mg cap taken 3 times daily.
Sachet: 1 sachet dissolved in a glass of water once daily.
Viartril-S is preferably taken at meals.
Contraindications
Hypersensitivity to glucosamine. As the active ingredient is obtained from seafood (shellfish), Viartril-S should not be given to patients who are allergic to shellfish. The powder for oral solution contains aspartame and is therefore contraindicated in patients with phenylketonuria.
Special Precautions
Patients with severe hepatic or renal insufficiency should be monitored while on Viartril-S. Viartril-S contains sodium 150 mg/daily dose to be taken into consideration by patients on a controlled sodium diet.
Side Effects
The clinical trials have shown the good tolerability of Viartril-S. Undesirable effects have been observed in a low proportion of patients. They were transient, of minor entity and included: Cardiovascular: Peripheral oedema, tachycardia were reported in a few patients following larger clinical trials investigating oral administration in osteoarthritis. Causal relationship has not been established.
Central Nervous System: Drowsiness, headache, somnolence, insomnia have been observed rarely during therapy.
Gastrointestinal: Nausea, vomiting, diarrhoea, dyspepsia or epigastric pain, flatulence, constipation, heartburn and anorexia have been described rarely during oral therapy with glucosamine.
Skin: Skin reactions eg, cutaneous rash, erythema, pruritus, have been reported with therapeutic administration of glucosamine. Occasionally, contact dermatitis, papular rash, urticaria and eczema may occur.
Isolated cases of hair loss, allergic reactions, visual disturbances and oedema were observed.
ATC Classification
M01AX05 - glucosamine ; Belongs to the class of other non-steroidal antiinflammatory and antirheumatic products.
Presentation/Packing
Cap 500 mg x 60's, 90's. Powd for oral soln (sachet) 1500 mg x 30's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in